All Articles
A brief overview of cancer therapies approved by the FDA between June 1, 2017, and July 30, 2017. Read More ›
Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults. Read More ›